Kasee Wiesen, APRN
Primary Care · Fremont, NENPI 1487214664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2023 at $864 and has fallen 77.3% since, to $197 in 2025. Among primary care clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$704
- Amgen$340
- Otsuka America Pharmaceutical, Inc.$326
- Pfizer$135
- Novo Nordisk$134
- Boehringer Ingelheim$121
- plus $874 from 29 others
What the payments were for
- Food & beverage$2,58998%
- Other$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $704 |
| Amgen | 23 | $340 |
| Otsuka America Pharmaceutical, Inc. | 21 | $326 |
| Pfizer | 9 | $135 |
| Novo Nordisk | 9 | $134 |
| Boehringer Ingelheim | 7 | $121 |
| AstraZeneca | 7 | $105 |
| Johnson & Johnson | 7 | $101 |
| Lilly USA, LLC | 4 | $58 |
| Bayer | 4 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Novartis | 3 | $50 |
| Welch Allyn | 1 | $45 |
| Genentech USA, Inc. | 2 | $32 |
| Ardelyx, Inc. | 2 | $31 |
| Boston Scientific | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Gilead | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| GSK | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Zealand Pharma US, Inc. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
How this compares
$2,634 in reported general payments places this provider in the 90th percentile of 65 primary care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $34,141 |
| OzempicSemaglutide | 35 | $33,346 |
| JardianceEmpagliflozin | 28 | $29,311 |
| Potassium Chloride | 61 | $2,225 |
| Atorvastatin Calcium | 202 | $1,635 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,543 |
| Omeprazole | 116 | $1,051 |
| SynthroidLevothyroxine Sodium | 17 | $886 |
| Levothyroxine Sodium | 113 | $724 |
| Pantoprazole Sodium | 42 | $698 |
| Metoprolol Succinate | 53 | $620 |
| Gabapentin | 36 | $612 |
| Pravastatin Sodium | 67 | $609 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $599 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $135 | $34,14147 claims |
| Novo NordiskOzempic | $134 | $33,34635 claims |
| Boehringer IngelheimJardiance | $121 | $29,31128 claims |
| AbbVieSynthroid | $704 | $88617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 primary care providers in Nebraska.
Other primary care in Fremont
- Jenna KoppOmaha$141K
- Alexis BarbosaOmaha$7K
- Rabia MoukradOmaha$6K
- Lisa BruhaOrd$5K
- Laurel DubaLincoln$5K
- Kerry Takedala Vista$4K
- Amy ArndtLincoln$2K
- Keri DillonOmaha$2K
- Paula Dawsonla Vista$2K
- Joseph AnthoneOmaha$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.